Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $6.6400 (-2.06%) ($6.6400 - $6.6400) on Wed. Feb. 17, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.5% (three month average) | RSI | 77 | Latest Price | $6.6400(-2.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.2% a day on average for past five trading days. | Weekly Trend | ADAP advances 8.9% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) IGOV(55%) VIXM(49%) IFRA(44%) XME(40%) IVE(39%) | Factors Impacting ADAP price | ADAP will decline at least -2.25% in a week (0% probabilities). TLT(-37%) CEMB(-29%) VCIT(-24%) VXX(-14%) UUP(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.25% (StdDev 4.5%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $6.66(-0.3%) | 10 Day Moving Average | $6.48(2.47%) | 20 Day Moving Average | $6.06(9.57%) | To recent high | -2.9% | To recent low | 28.2% | Market Cap | $1.027b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |